Gul Dusi

Abstract

The biopharmaceutical sector presents a paradox of historic proportions. Fourteen of the world's largest pharmaceutical companies have collectively committed over $600 billion in multi-year U.S. manufacturing and R&D investments, driven by GLP-1 blockbusters, domestic onshoring incentives, and record pipeline ambitions. Yet the innovation engine that must fill these factories is suffering its worst funding environment in a generation. Early-stage biotech venture capital has collapsed to a 20-year low as a share of U.S. startup investment, NIH faces a proposed 39.3% budget cut for FY 2026, and 39% of publicly traded biotechs are projected to exhaust their cash within 12 months. CBRE estimates that while $600 billion in manufacturing investment has been announced, only $60 billion is tied to specific projects with confirmed locations and amounts. This article synthesizes the most current data from DCAT, CBRE, PitchBook, EY, HSBC, Crunchbase, and primary company disclosures to diagnose the structural capital misallocation at the root of this paradox, draw lessons from the early 2000s biotech correction, and propose actionable interventions before a projected 10:1 manufacturing overcapacity crisis materializes by 2030.

$600B+

Pharma Mfg. Investment Announced (2025–2026)

30:1

Manufacturing vs. Early-Stage VC Ratio

39%

Biotechs with <12 Months Cash (EY 2025)

10:1

Projected Capacity-to- Approval Gap by 2030

1. Introduction: Two Economies Within One Industry

Modern biopharmaceuticals operate across two fundamentally misaligned economies. In the first economy—large-scale manufacturing—capital is abundant, strategic, and now approaching levels that defy historical comparison. In the second economy—early-stage discovery—capital is scarce, risk-averse, and contracting at an alarming rate. The collision of these opposing forces constitutes what Dusi Advisory Group terms “The Biotech Paradox.”

The manufacturing economy has reached a scale unimaginable even five years ago. According to DCAT Value Chain Insights, 14 major pharmaceutical companies announced cumulative multi-year U.S. manufacturing and R&D commitments totaling more than $600 billion across 2025 and early 2026. Driven by the extraordinary commercial success of GLP-1 receptor agonists, current U.S. domestic onshoring policy incentives, and looming patent cliffs demanding pipeline replenishment, the industry is executing a construction program of generational scale.

The discovery economy tells the opposite story. According to HSBC Innovation Banking, first-financing rounds for biotech startups fell from $2.6 billion in Q1 2025 to just $900 million in Q2 2025. Crunchbase data confirms that biotech’s share of all U.S. venture investment hit its lowest point in more than 20 years in 2025. EY’s 2025 Biotech Beyond Borders report found that 39% of assessed publicly traded biotechs were projected to run out of cash within 12 months—the highest level in at least six years. The proposed 39.3% NIH budget cut for FY 2026 threatens to compound this crisis by eliminating the foundational public research that underlies virtually every drug ever approved.

Core Thesis

The challenge facing biotech is not a shortage of aggregate capital. It is catastrophic misallocation: $600 billion flows into manufacturing while early-stage discovery funding hits a 20-year low. Without rebalancing, the industry is building factories that will have nothing to produce.

2. The $600 Billion Manufacturing Wave: Company-by-Company Analysis

2.1 The Unprecedented Scale of Commitment

The following table summarizes the major pharmaceutical manufacturing investment commitments announced by large companies in 2025 through early 2026, as compiled from DCAT Value Chain Insights, company press releases, and SEC filings. Together, these commitments represent the most concentrated capital deployment event in the history of pharmaceutical manufacturing.

CompanU.S. CommitmenTimeline

ocusreas

AbbVie

$100 billion

10 years

Immunology, neuroscience, oncology API; AI-integrated facilities

Merck & Co.

$70 billion

Multi-year

Keytruda biologics, vaccines, small molecules; Virginia, N. Carolina, Delaware, Kansas

Pfizer

$70 billion

Multi-year

Broad pipeline manufacturing; domestic API and fill-finish

AstraZeneca

$50 billion

Multi-year

Oncology, biologics, cell therapy; Virginia megasite ($4.5B)

Roche

$50 billion

5 years

Gene therapy, obesity drugs, diagnostics; Holly Springs NC + Cambridge MA

Eli Lilly

$50 billion+

2020–2030

GLP-1, ADC, biologics; Houston $6.5B, Virginia $5B, Alabama $6B, Wisconsin $3B

Gilead Sciences

$32 billion

Multi-year

AI-integrated biologics hub; 180,000 sq ft autonomous manufacturing

GSK

$30 billion

5 years

Respiratory, oncology; King of Prussia AI biologics facility ($1.2B)

Novartis

$23 billion

Multi-year

Radioligand therapy; 4th U.S. RLT facility in Winter Park, FL

J&J

$55 billion

4 years

Biologics, MedTech, oncology; Wilson NC $2B biologics plant

Sanofi

$20 billion

Multi-year

Vaccines, immunology, specialty care

Novo Nordisk

$4.1 billion

Multi-year

GLP-1 supply; Holly Springs NC groundbreaking Jan 2025

Amgen

$3 billion

Multi-year

Biologics; Holly Springs NC + Ohio fermentation expansion ($1.4B)

Biogen

$2 billion

Multi-year

Neuroscience, rare disease manufacturing

Source: DCAT Value Chain Insights (February 2026); company SEC filings and press releases, 2025–2026.

2.2 The Critical CBRE Caveat

While these commitments are unprecedented in scale, CBRE provided essential analytical context in a February 2026 webcast previewing its 2026 U.S. Life Sciences Trends report. Of approximately $600 billion in domestic investments announced in 2025, CBRE found that only $60 billion—just 10%—is tied to specific capital expenditure projects with confirmed amounts and locations. The remaining $540 billion represents multi-year intentions that have yet to be translated into ground-breaking announcements, permits, or contracted construction.

As Ian Anderson, CBRE’s senior director of research, stated: “If you take them at their word, that means you have about another $540 billion worth of these investments that are going to transpire over the next several years.” Industry specialists further note that even committed projects face a three-to-four-year timeframe for substantial capacity modifications, reflecting extended lead times for facility development, equipment validation, and regulatory approval. Most plants are slated to come online between 2027 and 2030. None will be operational before 2026.

2.3 The Policy-Driven Onshoring Context

A significant portion of the manufacturing investment wave is driven not purely by commercial opportunity but by current U.S. trade and industrial policy, which has introduced new incentives for domestic pharmaceutical production. Several major companies have announced expanded U.S. commitments framed around domestic operations, supply chain resilience, and alignment with federal procurement priorities. Johnson & Johnson and AbbVie have each structured voluntary investment arrangements with the federal government linking expanded domestic operations to broader commercial and regulatory frameworks.

This policy-linked investment context introduces a structural consideration for planning purposes: some portion of the $540 billion in uncommitted investment intentions is contingent on the current policy environment remaining intact. Infrastructure developers and ecosystem planners should model scenarios in which policy incentives shift, ensuring that facility investment cases are grounded in commercial demand fundamentals rather than policy tailwinds alone.

West Monroe’s 2026 Life Sciences Industry Outlook cautions that while expanding U.S. manufacturing may make sense for high-volume products, companies “should anticipate tight labor markets and longer lead times for capacity rollout.” Industry analyst Stefan Fath raises a question now circulating at the highest levels of pharma strategy: “In 2026, it will be interesting to see how U.S. capacity expansions will influence the European manufacturing landscape. Will we see overcapacity, especially in sterile fill and finish where extraordinary investments happened? Will we see shutdowns and closures?”

3. Anatomy of the Innovation Drought

3.1 The Collapse of Early-Stage Funding

While manufacturing capital flows at record velocity, the headwaters of pharmaceutical innovation are running dry. Seed through Series B funding rounds for discovery-stage biotechs are down approximately 25% from peak levels. HSBC data shows Q2 2025 represented the worst quarter for biotech first-financing rounds in five quarters, at just $900 million total. By mid-2025, U.S. biotech startups had raised just $8.2 billion in seed and early-stage funding—on pace for the lowest annual total in years.

Crunchbase notes that the shrinking share of funding going to biotech reflects not only weaker investor enthusiasm for the sector but also the gravitational pull of artificial intelligence investments diverting risk capital. The capital that does flow to biotech increasingly bypasses the discovery stage entirely: late-stage private equity surged approximately 30% year-over-year in 2024, driven by Series C and D rounds in companies with de-risked assets approaching commercialization. Investors demonstrate a clear preference for molecules that have cleared Phase II or Phase III clinical trials, where failure risk is substantially lower.

3.2 The Public Market Shutdown and H2 2025 Recovery

The public market for biotech IPOs effectively ceased functioning in the first half of 2025. By mid-year, only seven biotech companies had priced IPOs, with no large offerings since mid-February. The median stock price decline for the 2024 biotech IPO class was 70% by mid-year, rendering the public exit path economically unattractive.

The second half of 2025 showed nascent signs of recovery. According to BioPharma Dive’s January 2026 five-questions outlook, several indicators of sector health—from stock performance to deals and financings—turned positive in H2 2025. Generalist investors who had abandoned biotech during a lengthy downturn began to return cautiously. Multiple investment banks issued positive near-term outlooks in their December 2025 reports. However, BioPharma Dive notes that “sentiment could change quickly,” particularly given ongoing uncertainty from evolving trade policy, regulatory leadership transitions, and drug pricing negotiations.

Critically, even this partial recovery is concentrated in later-stage, de-risked assets. The structural deficit in early-stage discovery funding remains unaddressed, with PwC noting that patent expirations will put $47 billion in pharmaceutical sales at risk over the next four years—creating urgent M&A pressure that further diverts capital from discovery to commercial-stage acquisitions.

3.3 The NIH Crisis

The deterioration of private early-stage funding is simultaneously compounded by an unprecedented contraction in public research investment. The current administration’s proposed FY 2026 budget requests a 39.3% cut to NIH, reducing it from approximately $48 billion to $27.5 billion annually. In operational terms, new and competitive grants at NIH in 2025 were already running more than 40% below prior-year disbursement levels. Between February and May 2025, federal grant reviews terminated NIH-funded projects across 370 institutions, with Massachusetts alone losing over $1.1 billion in unspent funding.

The long-term innovation implications are quantified in a landmark MIT Sloan analysis published in Science: a 40% reduction in NIH funding over the period 1980–2007 would have affected more than 50% of new drug approvals since 2000. NIH-funded research contributed to more than 99% of FDA-approved drugs between 2010 and 2019. The current funding environment represents an existential threat not to the current drug pipeline, but to the pipeline of the 2030s—precisely the decade that will need to fill the manufacturing capacity now being built.

The workforce dimension compounds the scientific loss. Training grants collapsed 20% between 2024 and 2025, and early-career researchers dependent on NIH funding are seeking employment in pharmaceutical companies simply to maintain salary stability—a talent transfer from open, publication-driven basic research toward commercially constrained proprietary work that narrows the foundational science base.

The Cruelest Irony

A structural tension exists at the heart of current U.S. life sciences policy: the same industrial policy incentives accelerating $600B in manufacturing investment are occurring alongside proposed NIH budget reductions that would eliminate the foundational science that feeds those factories. Resolving this tension is the defining infrastructure planning challenge of the decade.

4. The Pipeline Mathematics: A Looming 10:1 Overcapacity Crisis

The arithmetic of pharmaceutical development makes the structural imbalance concrete. As of 2025, more than 23,000 drug candidates are in development globally. However, the Phase I to approval success rate is 9.6%, and the average development timeline from discovery to market is 10–12 years, producing an average of approximately 46.5 novel drug approvals per year. CBRE notes that the FDA’s most recent 10-year average of new drug approvals was 59% higher than the preceding decade, and 2025’s 46 approvals matched that average—a signal of stable but fundamentally limited pipeline throughput.

Against this approval throughput, current manufacturing CapEx is building capacity for an estimated 500–600 new drugs per year. The resulting Capacity-to-Approval Gap is projected to reach 10:1 by 2030 under current investment trajectories. This is not theoretical: the 2000s biotech correction produced manufacturing capacity utilization of 60–70% industry-wide, with some facilities operating below 50% capacity—and that correction arose from a far smaller investment imbalance than today’s.

23,000+

Global Drug Candidates in Development

9.6%

Phase I to Approval Success Rate

46.5

Avg. Annual Novel Drug Approvals

10:1

Projected Capacity vs. Approvals by 2030

The 2000s precedent is instructive. Following the dot-com bust, early-stage venture funding for biotech fell by 70%. Manufacturing investment continued on momentum from prior projections, creating a glut precisely as drug approvals slowed. By 2006–2008, new drug applications declined 15% from late 1990s levels, and manufacturing infrastructure sat largely intact but underutilized. Capacity utilization did not recover to pre-2000 levels until 2007–2008—a seven-year correction. The current imbalance is proportionally larger, and the manufacturing commitments now on record are far larger in absolute terms.

The most targeted new investments provide some buffer: Lilly’s Virginia $5B plant focuses on antibody-drug conjugates; Gilead’s $32B program features a 180,000 sq ft autonomous robotics hub; Novartis’s Winter Park facility specializes in radioligand therapy. These platform-specific investments serve near-term commercial demand. The overcapacity risk is greatest in generalist biologics fill-finish capacity—the precise segment where, as PharmaSource notes, “crazy investments happened” across multiple companies simultaneously.

5. The AI and Regulatory Acceleration Variable: Does It Change the Math?

Two structural developments have the potential to materially alter the pipeline mathematics described in Section 4: the emergence of AI-accelerated drug discovery platforms compressing traditional timelines, and the FDA’s landmark 2026 shift to a single-pivotal-trial approval standard. Together, proponents argue these forces could meaningfully close the gap between the rate of manufacturing investment and the rate of pipeline output. A rigorous examination of the evidence, however, reveals a more nuanced conclusion: AI and regulatory acceleration create a genuine long-range opportunity but do not resolve the near-term overcapacity risk within the timeframe of the factories now being built.

5.1 The Current State of AI-Driven Drug Discovery

AI has graduated from experimental curiosity to clinical-stage reality. According to a 2025 ScienceDirect landscape review, AI-designed therapeutics are now in human trials across diverse therapeutic areas, with over 200 AI-originated molecules in clinical development globally. Key milestones include: Insilico Medicine’s Rentosertib (ISM001-055), targeting idiopathic pulmonary fibrosis, which progressed from target identification to a preclinical candidate in just 18 months at a cost of approximately $150,000—a process that traditionally requires 4–6 years; the Recursion–Exscientia merger, which integrated phenomic screening with automated precision chemistry into a full end-to-end platform; and Schrödinger’s physics-enabled zasocitinib (TAK-279), which advanced into Phase III trials—the furthest stage reached by an AI-designed molecule as of 2026. Alphabet’s Isomorphic Labs, leveraging AlphaFold Nobel Prize-winning structural biology, is now preparing to dose its first patients in oncology trials.

The 2025 drug discovery landscape saw its highest-ever single-year jump in Investigational New Drug (IND) filings for AI-originated molecules, driven by Insilico Medicine, Recursion, BenevolentAI, Absci, and Generate Biomedicines. Foundational tooling advanced dramatically: Boltz-2, an open-source model from MIT and Recursion, delivered near physics-level accuracy for binding affinity predictions at speeds up to 1,000x faster than traditional simulations; Chai Discovery’s Chai-2 achieved 16–20% hit rates in antibody design—a 100x improvement over prior computational benchmarks. Eli Lilly partnered with NVIDIA to launch TuneLab, an AI platform designed to train and deploy models across the entire discovery-to-development continuum. Early Phase I data for AI-discovered drugs suggests potential success rates of 80–90%—compared to the historical average of 40–65%—indicating that AI may be filtering out poor candidates before they reach human trials, though this observation is based on a limited sample and experts caution against over-interpretation.

5.2 FDA Regulatory Acceleration: The Single-Trial Standard

In February 2026, the FDA announced its most significant reform to drug approval standards since 1998: the shift from requiring two adequate and well-controlled clinical trials to accepting one pivotal trial as the new default, combined with confirmatory evidence. Published in the New England Journal of Medicine, the policy rationale states: “In 2026, there are powerful alternative ways to feel assured that our products help people live longer or better than requiring manufacturers to test them yet again.” Confirmatory evidence can now include mechanistic data, biomarker endpoints, real-world evidence, animal models, and AI-generated biological plausibility assessments. This reform applies across all therapeutic areas—not just oncology and rare diseases, where single-trial approval has long been standard practice—potentially extending acceleration to neuropsychiatry, metabolic disease, and immunology.

Industry reaction has been measured rather than euphoric. AgencyIQ data reveals that 66% of all new molecular entities approved by the FDA’s Center for Drug Evaluation and Research in 2024 already relied on evidence from a single clinical trial—suggesting the formal policy change codifies existing practice more than it creates a new paradigm. GlobalData senior analyst Sonnika Lamont noted: “Clear endpoints and robust study design are now central, bringing the FDA’s approach into closer alignment with EMA and MHRA practices, which have long accepted approvals based on a single compelling pivotal trial.” Separately, the FDA launched the Commissioner’s National Priority Voucher (CNPV) program in mid-2025, which compresses review periods to approximately 1–2 months for therapies deemed to address critical national health priorities—including the February 2026 approval of Hernexeos for non-small cell lung cancer just 44 days after filing.

5.3 The Comparative Pipeline Scenario Analysis

To assess whether AI discovery and regulatory acceleration materially change the manufacturing overcapacity equation, three scenarios can be modeled against the baseline pipeline mathematics established in Section 4.

Scenario

Projected Annual Approvals by 2030

Capacity-to-Approval Gap

Manufacturing Outlook

Baseline (No AI, Status Quo FDA)

~50–55 / year

~9:1 to 10:1

Severe overcapacity. Significant stranded assets in generalist fill-finish.

Moderate AI + Single-Trial FDA (Most Likely)

~70–90 / year by 2030–2032

~5:1 to 7:1

Still overbuilt. Overcapacity materializes 2027–2030; gradual absorption by 2033–2035.

Full AI Transformation + Regulatory Compression (Optimistic)

~150–200 / year (Morgan Stanley 50-drug AI upside + regulatory boost)

~2.5:1 to 3:1

Moderate overcapacity. Manageable with flexible/modular facility design. Not achievable before 2032.

Sources: Morgan Stanley AI drug analysis; Axis Intelligence AI Drug Discovery 2026; FDA CDER 2025 approval data; Drug Target Review 2026 forecast.

5.4 Critical Constraints: Why AI Does Not Resolve the Near-Term Gap

The optimistic scenario is real but not near-term. Four structural constraints prevent AI and regulatory acceleration from resolving the manufacturing overcapacity risk within the 2027–2030 window in which the factories now being built will come online.

Constraint 1 – The Clinical Trial Bottleneck Persists. AI compresses pre-clinical and target identification timelines dramatically—from 4–6 years to 18 months in the best-documented cases. However, it does not yet compress Phase I, II, or III clinical trial duration, which still requires patient recruitment, safety monitoring, and follow-up periods governed by biology, not algorithms. A drug that enters Phase I today still requires a minimum of 5–7 years to reach approval even under the new single-trial standard. No AI-originated drug has yet completed a Phase III trial as of March 2026. Rentosertib is the closest candidate, potentially beginning Phase III in 2026–2027, with approval no earlier than 2028–2029.

Constraint 2 – Capital Starvation Limits the AI Pipeline. AI drug discovery platforms require substantial data, compute infrastructure, and wet-lab validation capital. The same early-stage funding collapse documented in Section 3—seed and Series A rounds down 25% from peak, biotech at a 20-year low as a share of U.S. VC—is directly constraining the AI discovery pipeline. AI is not exempt from the capital drought; it is subject to it. A Morgan Stanley analysis estimates that even modest AI improvements in early-stage success rates could yield an additional 50 novel therapies over a 10-year period—a meaningful but gradual contribution, not a step-change that resolves a 10:1 overcapacity gap by 2030.

Constraint 3 – Regulatory Evolution Does Not Equal Regulatory Reduction. The single-trial standard does not eliminate evidentiary requirements; it resequences them. Experts at UC Davis warn of an “RWE mortgage”: the FDA is accepting less pre-market data in exchange for aggressive post-market surveillance requirements, effectively shifting evidentiary generation into the post-approval period. This compresses time-to-approval but increases post-launch operational complexity and creates new manufacturing supply chain demands around real-world evidence collection. Critically, the single-trial standard was already the effective practice in 66% of 2024 NME approvals—meaning the incremental acceleration from the formal policy change is narrower than headlines suggest.

Constraint 4 – Manufacturing Modality Mismatch. AI drug discovery has demonstrated its strongest results in small molecules, targeted oncology, rare diseases, and fibrosis—therapeutic areas that predominantly use oral dosage forms, ADCs, and targeted biologics, not the large-volume parenteral biologics for which the majority of current CapEx is being deployed. The GLP-1 peptide manufacturing now being built at massive scale by Lilly and Novo Nordisk requires highly specialized API synthesis infrastructure. AI-discovered drugs entering the pipeline from 2026 onward are unlikely to be large-volume GLP-1 analogs requiring the same platform—creating a potential modality mismatch between what the new pipeline produces and what the new factories are designed to make.

5.5 The Net Verdict: Still Overbuilt, But the Long-Range Picture Improves

The honest answer to the central question—does AI-driven discovery and FDA acceleration resolve the overcapacity risk?—is: not within the critical window. The facilities now under construction will come online between 2027 and 2030. The AI drugs currently entering Phase I will not produce approvable Phase III data until 2028 at the earliest, with commercially significant volume not materializing until the mid-2030s. The manufacturing investment boom is structurally premature relative to the innovation timeline, even accounting for AI acceleration and the new single-trial standard.

However, the longer-range picture is meaningfully better than the baseline scenario suggests. If AI delivers even a moderate portion of its projected pipeline contribution—the Morgan Stanley 50-drug upside over a decade, combined with the throughput gains from AI’s documented 80–90% Phase I success rate improvements versus the historical 40–65%—the 10:1 overcapacity gap narrows progressively through the 2030s toward a more manageable 3:1 to 5:1 ratio. The critical implication for infrastructure planning is this: facilities designed for maximum fixed capacity around today’s dominant modalities face the greatest stranded-asset risk; facilities designed with modularity, platform flexibility, and the ability to pivot to novel small molecules, ADCs, and gene therapies are significantly better positioned to absorb the AI-driven pipeline as it matures. This is not a reason to stop building—it is a reason to build smarter.

6. Structural Drivers of Misallocation

6.1 The Rational Investor Trap

Capital misallocation reflects rational behavior within a structurally dysfunctional system. Late-stage assets carry lower failure risk, shorter time horizons, and clearer return profiles—all characteristics that align with institutional fund structures and LP expectations. Early-stage discovery carries 90%+ failure rates and 10–12 year time horizons that are incompatible with most venture capital architectures. The result is that each individual investment decision is rational while the collective outcome is systemically damaging.

The China biotech ecosystem has emerged as an unexpected accelerant of this dynamic. BioPharma Dive reports that more than 60 licensing deals were struck between China-based drugmakers and U.S. or European companies in 2025, representing at one point a full third of the industry’s licensing spending. Western companies are increasingly acquiring late-stage Chinese molecules rather than funding early-stage domestic discovery—a capital allocation pattern that further reduces domestic discovery investment while the companies themselves report robust pipeline statistics.

6.2 The Translational Valley of Death

Even where discovery-stage funding exists, a critical structural gap persists between proof-of-concept and scalable manufacturing: the Chemistry, Manufacturing and Controls (CMC) development valley of death. Companies must survive 18–36 months of expensive process development and regulatory preparation with minimal external support. No major federal funding program is specifically designed to bridge SBIR programs and venture capital for this middle translational stage—a gap that claims more promising companies than scientific failure.

The fragmentation of existing programs compounds this problem. A founder pursuing an NIH SBIR grant, a state innovation loan, and incubator space faces three completely different application processes with no coordination. Decision timelines of 12–18 months are structurally incompatible with six-month runway realities. As the second Dusi Advisory Group white paper observes: “entrepreneurs see a maze, not a map.”

7. Case Studies: What Bridge Architecture Looks Like

NCATS – Proof of Concept Funding at Scale

NCATS’s REACH Proof of Concept program funded over 350 projects generating more than $1 billion in follow-on investment. Its rare disease program has supported 60+ programs, with 12 reaching clinical trials and 3 achieving FDA approval since 2015. The model succeeds because it explicitly targets the valley of death with de-risking capital designed to prepare discoveries for commercial investment.

Massachusetts Life Sciences Center – Shared Infrastructure

The MLSC has invested $1.2 billion in shared infrastructure, supporting 400+ companies and generating $8.4 billion in economic impact. The shared GMP manufacturing model reduces capital barriers that prevent discovery-stage companies from advancing toward clinical validation—directly addressing the translational gap.

Portal Innovations – The Lab-Plus-Fund Model

Portal Innovations operates lab facilities combined with investment funds in Chicago, Atlanta, and Houston, providing both physical infrastructure and capital under one roof. By combining wet lab access, equipment sharing, and direct follow-on capital connections, Portal reduces the friction that kills many promising companies in their first two years of operation.

Indiana Biosciences Research Institute – Cross-Sector Partnership

IBRI’s collaborative model spanning academia, industry, and government facilitated $2.8 billion in follow-on investment and created over 1,200 high-skilled jobs. The cross-sector architecture demonstrates that the funding gap is bridgeable when institutional design aligns incentives across research, capital, and infrastructure.

8. Policy and Investment Recommendations

7.1 Stabilize and Reorient Public Research Funding

Congress must reject the proposed 39.3% NIH cut for FY 2026. The mathematical relationship between NIH investment and drug approvals—with NIH-funded research contributing to more than 99% of FDA-approved drugs between 2010 and 2019—makes this the highest-leverage policy intervention available. NIH appropriations should be stabilized with multi-year budget visibility. Grant success rates must be restored. Training grants must be reinstated as the primary pipeline for early-career scientists. The 15% indirect cost rate cap should be reversed to negotiated institutional rates.

7.2 Create Dedicated Translational Bridge Capital

Federal programs should create dedicated translation funds of $2–5 million specifically targeting CMC development, manufacturing process optimization, and regulatory pathway preparation, with 90-day decision timelines. Expanding REACH-style programs to include manufacturing readiness would represent high-leverage investment. Regional CMC Centers providing shared infrastructure for process development accessible to multiple companies would reduce the capital barriers that kill promising molecules before they can attract private investment.

7.3 Build the Ladder, Not the Maze

A unified federal portal consolidating all available programs—NIH, NSF, BARDA, ARPA-H, state programs, and certified private incubators—with transparent eligibility criteria and coordinated timelines would dramatically reduce the administrative burden currently killing promising companies through distraction. Program milestones should be aligned so that completing one phase naturally positions companies for the next, with fast-track mechanisms where success in earlier-stage programs creates preference in later-stage applications.

7.4 Align Manufacturing Investment with Discovery Investment

The $540 billion in uncommitted manufacturing investment intentions provides a significant policy window. Federal and state governments should structure co-investment frameworks that explicitly link manufacturing incentives and tax credits to matching investment in early-stage discovery or translational infrastructure. Companies making large-scale manufacturing commitments should be encouraged\u2014through tax structure, grant priority, and public-private partnership design\u2014to demonstrate proportional investment in the pipeline that will fill that manufacturing capacity.

7.5 Develop Modular GMP Campuses as a Real Estate Asset Class

The most capital-efficient mechanism for bridging the discovery-to-manufacturing gap is modular GMP campus development—pilot-scale shared manufacturing facilities sited near translational research hubs. Real estate developers and institutional investors should recognize the asymmetric opportunity: by positioning integrated campuses combining capital-efficient GMP manufacturing with workforce development infrastructure, they capture value from the translation gap rather than competing in the overcrowded commercial manufacturing market. Manufacturing-as-a-Service models that reduce capital barriers for discovery-stage biotechs represent a structural innovation in facility design with the potential to significantly improve pipeline throughput for the 2030s.

9. Conclusion: The Window Is Narrowing

The Biotech Paradox—$600 billion in manufacturing investment alongside a 20-year low in discovery funding—is not an inevitable feature of the biopharmaceutical landscape. It is the predictable consequence of rational individual behavior within a structurally dysfunctional system: one that provides enormous rewards for late-stage risk reduction and wholly inadequate incentives for the foundational discovery that creates the molecules those factories will need to produce.

The quantitative case for urgency is unambiguous. A projected 10:1 capacity-to-approval gap by 2030, a proposed 39.3% NIH budget cut, a collapse in early-stage VC to 20-year lows, and a 39% cash-runway crisis among publicly traded biotechs collectively define a sector whose near-term abundance masks a medium-term crisis. The 2003–2008 manufacturing overcapacity correction—arising from a far smaller imbalance—required seven years to resolve. The current imbalance is proportionally and absolutely larger.

The manufacturing commitments now on record will begin converting to shovels in the ground between 2026 and 2028. The molecules that will fill those facilities must begin their discovery journeys now. Drug development timelines of 10–12 years mean that the discovery funding decisions made in 2026 will determine what is available for commercialization in 2036–2038—precisely the period when the factories now being built will reach full operational capacity.

As Dusi Advisory Group’s second white paper concludes: the breakthrough therapies of the next decade already exist in laboratories across America. Our job is ensuring they survive the journey to patients—and that the factories being built to produce them will have something to manufacture when they open their doors.

References and Data Sources

AbbVie Inc. (2026). U.S. manufacturing investment announcements, January–February 2026. Press releases.

Azoulay, P. et al. (2025). ‘What if NIH had been 40% smaller?’ Science, September 25, 2025. DOI: 10.1126/science.aeb1564.

BioPharma Dive. (2026). ‘Five questions facing biopharma in 2026.’ January 12, 2026.

BioPharma Dive. (2025). ‘Biotech startup funding dried up in second quarter, HSBC finds.’ July 2025.

BioSpace. (2025). ‘More than one-third of biotechs have under a year of cash left, EY finds.’ June 2025.

CBRE. (2026). 2026 U.S. Life Sciences Trends Report (preview). Webcast, February 25, 2026.

Clinical Leader. (2025). Global pharmaceutical pipeline database.

Crunchbase. (2025). ‘Biotech share of U.S. funding hits lowest point in Crunchbase history.’ October 2025.

DCAT Value Chain Insights. (2026). ‘Bio/Pharma Outlook 2026: The Year Ahead.’ January 9, 2026.

DCAT Value Chain Insights. (2026). ‘Big Pharma Outlook: CEOs Making the Moves.’ February 2026.

DCAT Value Chain Insights. (2025). ‘Big Pharma & US Manufacturing Investment.’ August 2025.

Dusi Advisory Group. (2025). ‘The Biotech Paradox: Manufacturing Boom Meets Innovation Drought.’ White paper.

Dusi Advisory Group. (2025). ‘Solving the Biotech Paradox.’ White paper.

EY. (2025). Biotechnology Beyond Borders: 2025 Annual Report.

Fierce Biotech. (2025). Annual Biotech Graveyard Reports, 2023–2025.

IntuitionLabs. (2025). ‘New Drug Manufacturing Plants: A 2025 Guide & Analysis.’ October 2025.

Nature Communications. (2025). Clinical trial success rate analysis.

Pharma Manufacturing. (2026). ‘Big Pharma’s $600B US investment plans are short on details: CBRE.’ February 2026.

PharmaExec. (2026). ‘Pharma Manufacturing Roundup: AbbVie Invests $380 Million.’ February 28, 2026.

PharmaSource. (2026). ‘What to Expect in Pharma Manufacturing in 2026.’ January 2026.

PhRMA. (2025). Member company investment pledges. PhRMA Annual Report.

PitchBook. (2025). Biotech VC fundraising data, H1 2025.

PwC. (2026). 29th Global CEO Survey. 2026 edition.

Richmond Group USA. (2026). ‘2026 Pharma Investments: Big Bets Reshaping the Drug Industry.’ January 27, 2026.

Supply Chain Digital. (2026). ‘Inside Big Pharma’s Strategic Shift to US Onshoring.’ January 14, 2026.

Washington Examiner. (2025). ‘Merck announces $70 billion US manufacturing investment.’ October 20, 2025.

West Monroe. (2026). 2026 Life Sciences Industry Outlook.

ZS Associates. (2026). ‘Pharma Industry Outlook 2026.’